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Abstract: Brucellosis is a highly contagious zoonosis worldwide with economic and public health
impacts. The aim of the present study was to identify Brucella (B.) spp. isolated from animal
populations located in different districts of Egypt and to determine their antimicrobial resistance.
In total, 34-suspected Brucella isolates were recovered from lymph nodes, milk, and fetal abomasal
contents of infected cattle, buffaloes, sheep, and goats from nine districts in Egypt. The isolates were
identified by microbiological methods and matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI-TOF MS). Differentiation and genotyping were confirmed using multiplex
PCR for B. abortus, Brucella melitensis, Brucella ovis, and Brucella suis (AMOS) and Bruce-ladder PCR.
Antimicrobial susceptibility testing against clinically used antimicrobial agents (chloramphenicol,
ciprofloxacin, erythromycin, gentamicin, imipenem, rifampicin, streptomycin, and tetracycline) was
performed using E-Test. The antimicrobial resistance-associated genes and mutations in Brucella
isolates were confirmed using molecular tools. In total, 29 Brucella isolates (eight B. abortus biovar 1
and 21 B. melitensis biovar 3) were identified and typed. The resistance of B. melitensis to ciprofloxacin,
erythromycin, imipenem, rifampicin, and streptomycin were 76.2%, 19.0%, 76.2%, 66.7%, and 4.8%,
respectively. Whereas, 25.0%, 87.5%, 25.0%, and 37.5% of B. abortus were resistant to ciprofloxacin,
erythromycin, imipenem, and rifampicin, respectively. Mutations in the rpoB gene associated with
rifampicin resistance were identified in all phenotypically resistant isolates. Mutations in gyrA
and gyrB genes associated with ciprofloxacin resistance were identified in four phenotypically
resistant isolates of B. melitensis. This is the first study highlighting the antimicrobial resistance in
Brucella isolated from different animal species in Egypt. Mutations detected in genes associated with
antimicrobial resistance unravel the molecular mechanisms of resistance in Brucella isolates from
Egypt. The mutations in the rpoB gene in phenotypically resistant B. abortus isolates in this study
were reported for the first time in Egypt.
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1. Introduction
Brucellosis is considered as a common bacterial zoonotic disease of high prevalence in countries
of the Middle East and the Mediterranean region, as well as some parts of Central and South America,
Africa, and Asia [1,2]. Brucellosis is caused by bacteria of various species of the genus Brucella (B.)
that are genetically highly related [3,4]. Brucella is a Gram negative, facultative intracellular pathogen
classically causing infections in sheep and goats (B. melitensis), rams (B. ovis), bovines (B. abortus),
canines (B. canis), pigs (B. suis), and rodents (B. neotomae) [5,6]. Brucellosis also affects terrestrial wildlife
(B. microti) and marine mammals (B. ceti and B. pinnipedialis) [7]. However, the cross infection of animal
species with brucellae has also been reported [8]. Brucellosis in livestock is causing high economic
losses to livestock industry due to poor health, debility and loss of quality livestock products [9]. In
humans, brucellosis causes severe acute febrile illness that becomes chronic if left untreated [10].
In developing countries, brucellosis is common but neglected disease, which has been endemic in
Egypt for thousands of years and is present with a high prevalence in animals today [11–14]. Prevalence
ranges from 2.47% to 26.66% in various livestock populations and this has a great socio-economic
impact [15]. In Egypt, B. abortus, B. suis and B. melitensis strains were isolated from livestock having
high levels of phylogenetic variability within each species [12]. The incidence of human brucellosis is
0.28–95 per 100,000 inhabitants per year in Egypt [16,17]. Humans get infected via the ingestion of
contaminated raw milk, unpasteurized dairy products, handling of infected animals, animal discharges
or dealing with Brucella cultures [18,19].
The diagnosis of brucellosis is still challenging and usually relies on serological tests [20], which
are applied in vitro (milk or blood). Exceptionally, in vivo (allergic tests) are used. The isolation of
brucellae and detection of Brucella DNA by PCR are the methods that allow definitive diagnosis [21].
Although confirmation of the disease is achieved by bacterial culture and identification, Brucella is
difficult to grow and bacterial culturing is time consuming. Additionally, this method poses a risk to
laboratory personnel and requires specific biosafety measures [22]. Hence, culture and biochemical
typing remain the “gold standard” for the diagnosis of Brucella infection [23], including biochemical
tests like CO2 requirement, H2S production, and dye sensitivity. Urease, oxidase, and catalase tests
are also used for the typing of Brucella spp. [24]. A comparatively new method like matrix-assisted
laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has emerged for
microbiological identification [25]. It is an economical, easy, rapid and accurate method based on the
automated analysis of the mass distribution of bacterial proteins [26]. A recently published study
indicates that MALDI-TOF MS can accurately identify 99.5% and 97% of Brucella strains at the genus
and species level, respectively that minimizing laboratory hazards. However, there are limitations in
terms of sub-species level identification [27]. Brucella identification and species differentiation can be
accomplished using genus-specific Brucella PCR (B4/B5), AMOS-PCR, and Bruce-ladder PCR [28–32].
The intracellular location of brucellae in reticuloendothelial cells and their predilection sites (e.g.,
bone) limit the penetration of most antibiotics. Antimicrobial regimes with quinolones, doxycycline,
rifampicin, streptomycin, and aminoglycoside alone or in combination are used to treat brucellosis [33].
Regular treatment failure and numerous reports of relapses of brucellosis following therapy exist
ranging from 5% to 15% in uncomplicated cases [34]. Recently, the antimicrobial resistance in Brucella
is emerging in brucellosis endemic regions of the world (e.g., Egypt, Qatar, Iran, Malaysia, and
China) [34].
There is no proper legislation in Egypt regulating the use of antimicrobials. Some compounds
such as quinolones, tetracycline, beta-lactams, aminoglycosides and imipenem are still overused
non-therapeutically in Egypt to treat various human infections [35–37]. This improper use of
antimicrobials results in the emergence of multidrug resistant bacteria [38–41]. The use of antimicrobials
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in farm animals to promote growth or as prophylaxis also contributes to the development of resistant
bacteria and plays a key role in their spread along the food chain [42]. Antimicrobial resistance in
zoonotic pathogens is an additional risk because it will limit disease treatment options in public
health and veterinary settings [43]. None of the available studies highlights detailed antimicrobial
susceptibility patterns of Brucella isolates from livestock in Egypt.
The use of antimicrobial susceptibility testing is the solution for appropriate control and treatment
of brucellosis [44,45]. Micro-dilution and/or gradient strip (E-test) methods are used to establish
minimum inhibitory concentration (MIC) for antimicrobials [45,46]. PCR assays and the subsequent
sequencing of genes associated with resistance are used to identify the genetic bases of resistance [47–49].
Resistance to commonly used antimicrobials is mediated by mutations of rpoB gene (rifampicin),
gyrA, gyrB, parC, parE genes (quinolones), erm, mef, msr (macrolides) or the presence of tet genes
(tetracyclines), mecA (beta-lactams) and floA (trimethoprim) [50]. Mutations in the rpoB and gyrA genes
may occur naturally or can be induced in vitro [45,47,51,52].
This study aimed to isolate, identify and biotype Brucella strains from livestock in various
regions of Egypt. Antimicrobial resistance and its genetic basis are to be investigated in the gained
Brucella isolates.
2. Materials and Methods
2.1. Isolation and Identification
A total of 34 suspected Brucella isolates were recovered from clinical specimens of lymph nodes,
milk and fetal stomach contents from infected cattle, buffaloes, sheep and goats located in Giza, Beheria,
Asyut, Qalyubia, Beni-Suef, Ismailia, Dakahlia, and Monufia governorates/districts in Egypt (Table 1).
Bacterial isolation and identification were performed in Biological Safety Level-3 (BSL-3) laboratory.
Isolates were inoculated on calf blood agar, Brucella medium and Brucella selective medium plates
(Oxoid GmbH, Wesel, Germany) at 37 ◦C in the absence and presence of 5–10% CO2 for up to 2 weeks.
Typically, round, glistening, pinpoint and honey drop-like cultures were picked and stained with Gram
and modified Ziehl-Neelsen staining (MZN) methods. Subsequent biochemical tests, motility test,
hemolysis on blood agar and agglutination with monospecific sera were performed [24,53]. Isolates
were stored at −20 ◦C for further processing.
Identification by MALDI-TOF MS
Bacterial identification was additionally carried out using MALDI-TOF MS as described
previously [27,54]. Briefly, pure cultures of suspected Brucella were obtained by incubating inoculated
chocolate PolyViteX (PVX) agar plates (bioMérieux, Marcy-l’Étoile, France) for 48 h at 37 ◦C in
the presence of 5% CO2. Samples were reliably inactivated in Biological Safety Level-3 laboratory.
Approximately 10 colonies from culture medium were suspended in 50 µL of sterile HPLC water and
mixed carefully. Formic acid (v/v 70%) was added for the inactivation of brucellae and for extraction
of proteins. Then, 1 µL of tested sample and Brucella reference strains were added onto spots of
a steel target plate. After inactivation, the plate was dried at room temperature followed by the
addition of 0.5 µL of 100% ethanol to each well. Finally, spots were overlaid with 1 µL of reconstituted
alpha-cyano-4-hydroxycinnamic acid (Bruker Daltonics, Billerica, MA, USA).
Spectra were acquired with an Ultraflex instrument (Bruker Daltonics GmbH, Bremen, Germany).
Analysis was done with the Biotyper 3.1 software (Bruker Daltonics GmbH, Germany) as per the
manufacturer’s instructions to exclude spectra with outlier peaks or anomalies.
Logarithmic score values (0–3.0) were determined by automatically calculating the proportion
of matching peaks and peak intensities between the test spectrum and the reference spectra in the
database. The identification was considered reliable when the score between 2.3 and 3.0. A logarithmic
score of 1.7–2.299 was reported as ‘probable genus identification’, indicating that identification was
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reliable only at the genus level. When the logarithmic score was <1.7, the spectrum was reported as
‘not reliable identification’, indicating that sample could not be identified.
2.2. Genomic DNA Extraction and Purification
DNA was extracted from heat inactivated pure Brucella culture (biomass) using the HighPure PCR
Template Preparation Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s
instructions. DNA quantity and purity were determined using a NanoDrop™ 1000 spectrophotometer
(Thermo Fisher Scientific, Wilmington, USA).
2.3. Molecular Identification and Differentiation
The presence of the Brucella genus-specific bscp31 gene [55] and Brucella-specific insertion sequence
711 (IS711) [29] was investigated for Brucella genus identification. Briefly, PCR was performed using
25 µL reaction mixture containing 18.3 µL HPLC water, 2.5 µL 10x PCR buffer (Genaxxon bioscience
GmbH, Ulm, Germany), 1 µl of 10mM dNTP (Thermo Fisher Scientific, USA), 1 µL each forward
(5′-TGG CTC GGT TGC CAA TAT CAA-3′) and reverse primer (5′ CGC GCT TGC CTT TCA GGT
CTG-3′) (Jena Bioscience, Germany), 0.2 µL of 5U/µL Taq-polymerase (Genaxxon bioscience GmbH,
Ulm, Germany) and 1 µL DNA template.
PCR condition was initiated by initial denaturation at 93 ◦C for 5 min, followed by 35 cycles of
denaturation at 90 ◦C for 60 s, annealing at 60 ◦C for 60 s and elongation at 72 ◦C for 60 s and final
elongation step at 72 ◦C for 5 min. PCR products (223 bp) were analyzed on 1.5% agarose gel, stained
with ethidium bromide, and visualized under UV light.
The AMOS-PCR was performed to differentiate Brucella species [29,32] followed by a multiplex
Bruce-ladder PCR assay for strain and biovar typing [30,56]. The list of primers and primer sequences for
AMOS-PCR and Bruce-ladder PCR were geared from previously published [29] and [30], respectively.
Briefly, for AMOS-PCR, PCR was performed using 25 µL reaction mixture containing 9.5 µL HPLC
water, 12.5 µL of 2x Qiagen Master mix (Qiagen, Germany), 1 µL of 10 pmol primer mix and 2 µL DNA
template. Initial denaturation at 95 ◦C for 5 min, was followed by 30 cycles of denaturation at 95 ◦C for
60 s, annealing at 58 ◦C for 2 min and elongation at 72 ◦C for 2 min and a final elongation step at 72 ◦C
for 5 min. The Bruce-ladder PCR was performed using 12.5 µL reaction mixture containing 4.25 µL
HPLC water, 6.25 µl of 2x Qiagen Master mix (Qiagen, Germany), 1 µL of 2 pmol/µL primer mix and 1
µL DNA template. Initial denaturation at 95 ◦C for 15 min, was followed by 25 cycles of denaturation
at 94 ◦C for 30 s, annealing at 58 ◦C for 90 s, elongation at 72 ◦C for 3 min and a final elongation step at
72 ◦C for 10 min.
The PCR products from each PCR were separated by electrophoresis using 1.5% agarose gels
(120 V for 60 min for conventional and AMOS-PCR and 130 V for 60 min for Bruce-ladder PCR). Gels
were stained with ethidium bromide and photographed using a gene snap camera (Syngene Pvt Ltd.,
Cambridge, UK).
2.4. Antimicrobial Susceptibility Testing
The antimicrobial susceptibility of B. melitensis and B. abortus isolates was performed against eight
clinically relevant antimicrobial agents (chloramphenicol, ciprofloxacin, erythromycin, gentamicin,
imipenem, rifampicin, streptomycin and tetracycline) using gradient strip method (E-test, bioMerieux,
Marcy L’Etoile, France) as described previously [48]. Briefly, a suspension of bacteria adjusted to 0.5
McFarland standard units was inoculated on Mueller-Hinton plates (Oxoid GmbH, Wesel, Germany)
supplemented with 5% sheep blood and the gradient strips were applied. The plates were incubated
at 37 ◦C with 5% CO2 for 48 h before reading. As MIC breakpoints for clinically used antimicrobials
are not yet established for brucellae, the guidelines for slow-growing bacteria (Haemophilus influenzae)
were used as an alternative [57]. Quality control assays were performed using E. coli (161008BR3642,
DSM 1103, ATCC 25922). The susceptibility profiles of Brucella isolates are presented as resistant and
susceptible using minimum inhibitory concentrations (MIC), MIC50 and MIC90. The interpretations
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were performed using CLSI (The Clinical and Laboratory Standards Institute) [57] and EUCAST (The
European Committee on Antimicrobial Susceptibility Testing) [58] using the criteria for slow growing
bacteria. For rifampin, the strains were also classified as intermediate (Table 2).
2.5. Molecular Detection of Antimicrobial Resistance-Associated Genes
The PCR assays were performed as described previously [47,49,52,59] to detect the antimicrobial
resistance-associated genes, i.e., catB, gyrA and gyrB, rpoB, Aac genes and tet genes for chloramphenicol,
ciprofloxacin, rifampicin, streptomycin, gentamicin and tetracycline, respectively (Supplementary
Table S1). The primers used for amplification of the rpoB gene were designed by using submitted
sequences for the rpoB gene of B. abortus (accession number AY562181) [47]. PCR was performed using
25 µL reaction mixture containing 2x Qiagen Mastermix, 10 pmol each forward and reverse primer
(Table 1) and 5 µl DNA template. PCR was carried out by initial denaturation at 95 ◦C for 10 min,
followed by 35 cycles of denaturation at 95 ◦C for 45 s, annealing (temperatures for each primer are
given in Table 1) for 60 s, elongation at 72 ◦C for 60 s and a final elongation step at 72 ◦C for 10 min.
Twenty microliters of each reaction mixture were analyzed by gel electrophoresis (1% agarose gel with
ethidium bromide).
2.6. PCR Amplicon Sequencing and Data Analysis
Amplified PCR products for gyrA, gyrB and rpoB genes were purified using Qiagen QIAquick
Gel extraction kit (Qiagen, Germany) and sent for sequencing (Eurofins Genomics Germany GmbH,
Ebersberg, Germany). All consensus sequences were aligned and compared to the reference Brucella
genes obtained from NCBI for detection and evaluation of nucleotide diversity and mutations using
the software Geneious® R11.1.5 (https://www.geneious.com). The sequences of gyrA (CP034103
and AE017223), gyrB (CP007760 and SDWB01000001) and rpoB (AY562181 and AY540346) genes of
B. melitensis and B. abortus were geared from Gene bank and used as reference. Amino acid sequences
were determined along with nucleotide sequences to identify missense mutations using BLAST.
3. Results
3.1. Microbiological Identification
Based on microbiological and biochemical characteristics, 21 strains were typed as B. melitensis
biovar 3, eight strains were B. abortus biovar 1 and five samples were identified as Achromobacter species
(Table 1). The results of MALDI-TOF MS confirmed five isolates as Achromobacter species while the
remaining 29 isolates were identified as Brucella species (Table 1).
3.2. Molecular Identification and Differentiation
Brucella DNA of 24 isolates from cattle, three from buffaloes, one from a sheep and one from a
goat were amplified with the genus specific assay. AMOS-PCR and Bruce-ladder PCR differentiated
these 21 isolates as B. melitensis (17 from cattle, two from buffaloes, 1 from a sheep and 1 from a goat)
and 8 isolates as B. abortus (seven from cattle and one from a buffalo). All isolates were confirmed as
field strains (Table 1).
3.3. Antimicrobial Susceptibility Profiling
The in vitro MIC values against eight antimicrobial agents of all 29 Brucella isolates were determined
by the gradient strip method (E-test). The MIC values along with MIC50 and MIC90 are summarized in
Table 2.
In this study, 76.19%, 19.04%, 76.19%, 66.66%, and 4.76% of the B. melitensis isolates were resistant
to ciprofloxacin, erythromycin, imipenem, rifampicin/rifampin and streptomycin, respectively. While,
25%, 87.5%, 25%, and 37.5% of B. abortus isolates were phenotypically resistant to ciprofloxacin,
erythromycin, imipenem and rifampicin/rifampin, respectively. All 29 Brucella isolates were sensitive
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to chloramphenicol, gentamicin, and tetracycline. Four isolates of B. melitensis (19.04%) and one
B. abortus isolate showed multidrug resistance against ciprofloxacin (fluoroquinolones), erythromycin
(macrolides), imipenem (carbapenems) and rifampicin (ansamycins).
3.4. Detection of Antimicrobial Resistance-Associated Genes and Mutations
Genes associated with antimicrobial resistance (catB, Aac and tet (tetA, tetB, tetM and tetO)
conferring resistance to chloramphenicol, streptomycin/gentamicin and tetracycline, respectively) were
not identified either in resistant or sensitive isolates. The gyrA, gyrB and rpoB genes were amplified in
all isolates.
Mutations in rpoB gene associated with a rifampicin-resistant B. melitensis and B. abortus phenotypes
were detected at different positions (Table 3).
Mutations in gyrA gene associated with phenotypic-ciprofloxacin resistance were detected at
positions 167 (ATG to AGG/methionine to arginine), 197 (CCC to CGC/proline to arginine), 202 (CGC
to AGC/arginine to serine), 235 (GGT to CGT/glycine to arginine), 941 (GCC to GAC/alanine to aspartic
acid), 944 (GTG to GAG/valine to glutamic acid), 944-945 (GTG to GGA/valine to glycine), 946 (GCC to
TCC/alanine to serine) and 962 (AAC to ACC/asparagine to threonine) in B. melitensis (Table 4).
Three-point mutations were also detected in gyrB gene at position 1141 (AAG to GAG/Lysine
to Glutamine), 1144 (ATC to CTC/Isoleucine to leucine) and 1421 (TCA to TTA/Serine to Leucine) in
phenotypically resistant B. melitensis isolates (Table 4).
Repeated mutations were detected at positions 676, 677 (TAC to CTC/tyrosine to leucine) and
1435 (AAG to CAG/lysine to glutamine) in the rpoB gene of phenotypic resistant B. melitensis isolates
while the same was recorded at position 2890 (CGT to GGT/arginine to glycine) in the rpoB gene of
B. abortus isolates. No mutation was detected in gyrA and gyrB gene of B. abortus strains.
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Sample Type of Sample Growth with CO2 Slide Agglutination A-M-R-Serum MALDI-TOF MS
Molecular
Identification
cBruc dBrusel eBBA A M R Result
18RB17227 Cattle Giza Lymph node + + + a+ve +ve b−ve B. melitensis 3 Brucella spp. (B. abortus) B. melitensis
18RB17228 Cattle Giza Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. abortus) B. melitensis
18RB17229 Cattle Giza Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella melitensis B. melitensis
18RB17230 Cattle Giza Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. melitensis) B. melitensis
18RB17231 Cattle Giza Lymph node + + + −ve −ve −ve * NA Achromobacter spp. -ve
18RB17232 Cattle Giza Lymph node + + + −ve −ve −ve NA Achromobacter spp. -ve
18RB17233 Cattle Giza Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17234 Cattle Giza Lymph node + + + −ve −ve −ve NA Achromobacter spp. -ve
18RB17235 Cattle Giza Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
18RB17236 Cattle Giza Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. melitensis) B. melitensis
18RB17237 Cattle Giza Lymph node + + + −ve −ve −ve NA Achromobacter spp. -ve
18RB17238 Cattle Giza Lymph node + + + +ve −ve −ve B. abortus 1 Brucella spp. (B. microti) B. melitensis
18RB17239 Cattle Giza Lymph node + + + −ve −ve −ve NA Achromobacter spp. -ve
18RB17240 Cattle Beheira Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
18RB17241 Cattle Beheira Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
18RB17242 Cattle Beheira Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17243 Cattle Beheira Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17244 Buffalo Asyut Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. abortus) B. melitensis
18RB17245 Buffalo Asyut Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17246 Goat Beni-Suef Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
18RB17247 Cattle Asyut Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. melitensis) B. melitensis
18RB17248 Cattle Qalyubia Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
18RB17249 Cattle Qalyubia Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. melitensis) B. melitensis
18RB17250 Sheep Beni-Suef Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. melitensis) B. melitensis
18RB17251 Cattle Beni-Suef Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
18RB17252 Cattle Ismailia Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. melitensis) B. melitensis







Sample Type of Sample Growth with CO2 Slide Agglutination A-M-R-Serum MALDI-TOF MS
Molecular
Identification
cBruc dBrusel eBBA A M R Result
18RB17253 Cattle Ismailia Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. abortus) B. melitensis
18RB17254 Cattle Ismailia Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. B. melitensis
18RB17255 Cattle Beheira Fetal stomachcontent +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17256 Cattle Dakahlia Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17257 Cattle Monufia Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17258 Cattle Monufia Milk + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. abortus) B. melitensis
18RB17259 Cattle Qalyubia Lymph node +/− +/− +/− +ve −ve −ve B. abortus 1 B. abortus B. abortus
18RB17260 Buffalo Qalyubia Lymph node + + + +ve +ve −ve B. melitensis 3 Brucella spp. (B. microti) B. melitensis
* NA-not applicable, a Positive, b Negative, c Brucella medium, d Brucella selective medium, e Brucella blood agar.
Table 2. Antimicrobial resistance profiles of 21 B. melitensis and 8 B. abortus isolated from livestock species in Egypt against 8 clinically used antibiotics using E-test.
Breakpoint and Minimal Inhibitory Concentration (MIC50, MIC90) for B. melitensis and B. abortus used in this study according to CLSI and EUCAST recorded for H.
influenzae [57,58] were provided.
Antibiotic Class















Chloramphenicol Phenicols ≤2 4 ≥8 0.0 1 2 0.0 0.25 0.5
Ciprofloxacin Fluoroquinolones ≤0.06 − >0.06 76.19 0.12 0.25 25.0 0.06 0.06
Erythromycin Macrolides − − ≥16 19.04 4 8 87.5 32 32
Gentamicin Aminoglycosides − − ≤4 0.0 11 11 0.0 0.12 0.5
Imipenem Carbapenems ≤2 − >2 76.19 8 8 25.0 1 4
Rifampicin Ansamycins ≤1 2 ≥4 66.66 4 8 37.5 2 4
Streptomycin Aminoglycosides − − ≤16 4.76 1 2 0.0 0.25 0.5
Tetracycline Tetracyclines ≤2 4 ≥8 0.0 0.06 0.12 0.0 0.03 0.12
−. Not determined
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Table 3. Detection of mutations in rpoB gene associated with rifampicin resistance in B. melitensis and B. abortus.
ID Brucella spp. RIF Resistance Mutation Sites Mutation Amino Acid Change NCBI(Accession No.)



























Serine to aspartic acid
Methionine to glycine
Glutamic acid to lysine
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Aspartic acid to glutamic acid
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ID Brucella spp. RIF Resistance Mutation Sites Mutation Amino Acid Change NCBI(Accession No.)

















Glutamic acid to glycine
Isoleucine to valine
Tyrosine to aspartic acid

















Table 4. Detection of mutations in gyrA and gyrB genes associated with ciprofloxacin resistance in B. melitensis.
ID Brucella spp. CIPResistance Gene Mutation Sites Mutation Amino Acid Change NCBI(Accession No.)



















Alanine to serine MN536678
18RB17238 B. melitensis 0.25 941944
GCC to GAC
GTG to GAG
Alanine to aspartic acid
Valine to glutamic acid MN536679
18RB17254 B. melitensis 0.12 962 AAC to ACC Asparagine to threonine MN536680
18RB17230 B. melitensis 0.5
gyrB
1144 ATC to CTC Isoleucine to leucine MN536681
18RB17244 B. melitensis 0.25 1141 AAG to GAG Lysine to Glutamine MN536682
18RB17252 B. melitensis 0.12 1421 TCA to TTA Serine to Leucine MN536683
18RB17254 B. melitensis 0.12 1421 TCA to TTA Serine to Leucine MN536684
Microorganisms 2019, 7, 603 13 of 19
4. Discussion
Brucellosis is a zoonotic disease of public health importance and is still endemic in many countries
including Egypt [17,20]. In this study, the phenotypic and molecular characterization of Brucella
isolates from cattle, buffaloes, sheep and goats obtained from different geographical locations of Egypt
was performed. Additionally, the molecular basis of antimicrobial resistance in Brucella isolates from
Egypt is reported for the first time. These results contribute to a better understanding of geographic
transmission and spread of brucellae in livestock in Egypt and pave a way for specific treatment and
control of the disease in animals and as well as in humans.
For the accurate diagnosis of brucellosis, isolation of bacteria or molecular proof along with
suggestive clinical signs is needed. Brucellae were isolated in this study from milk, lymph nodes and
fetal stomach contents as recommended in previous reports [24,60].
Twenty-one B. melitensis bv3 and 8 B. abortus bv1 were isolated from cattle, buffaloes, sheep and
goats from Giza, Beheria, Asyut, Qalyubia, Beni-Suef, Ismailia, Dakahlia and Monufia governorates.
Previous reports were described previously that Brucella was prevailing in the country [12]. The
isolation of B. melitensis from cattle and buffaloes in this study may be attributed to mixed farming of
large and small ruminants as mentioned previously [13].
Still brucellosis is a challenge to treat in humans, particularly after delayed diagnosis of the
infection. The WHO (World Health Organization) recommended treatment include high oral doses of
rifampicin, doxycycline or tetracycline and trimethoprim-sulfamethoxazole. Although streptomycin
and tetracycline are considered as powerful therapeutic agents against brucellosis, their higher toxicity
limits their use [52,61]. Quinolones are promising alternatives to treat human brucellosis as they have
good bioavailability and affinity for bone and soft tissues [51].
Only one study from Brazil reported reduced antimicrobial sensitivity in brucellae isolated from
cattle [62]. However, the emergence of brucellae isolated from humans phenotypically resistant to
ciprofloxacin, gentamycin, streptomycin, rifampicin and trimethoprim-sulfamethoxazole was reported
in Egypt, Iran, Qatar, China, Norway and Malaysia [46,48,63–65]. Phenotypically rifampicin resistant
B. melitensis isolates were also reported from Norway in imported cases from the Middle East, Asia or
Africa [45]. Probable rifampicin resistance was noted in 19% of a large collection of B. melitensis isolates
from humans in Egypt between 1999 to 2007 [65]. However, none of those isolates were investigated
further to confirm the basis of resistance or reduced susceptibility.
In this study, a notable phenotypic resistance against ciprofloxacin (76.19%) was detected in
B. melitensis strains isolated from animals. In contrast, none of the mentioned studies reported
ciprofloxacin resistance in clinical isolates of humans and animals before. However, antimicrobial
resistance against quinolones has been reported in in vitro studies of B. melitensis from Greece and
France [49,52].
An alarming high number of rifampicin resistant (66.66%) B. melitensis isolates was found in
this study. Previous reports from Egypt (19%), [65], Norway (24%) [45] and Kazakhstan (26.4%) [66]
described comparatively low resistance. Hence, these findings are in agreement with previously
published reports from Egypt that clearly showed an increase in antimicrobial resistance in various
other human pathogens [37]. Reduced rifampicin susceptibilities in B. melitensis strains were also
reported from Iran, Malaysia, China, and Kazakhstan [46,48,63,64,66].
The most striking finding of the present study was the emergence of phenotypic antimicrobial
resistance against erythromycin (19.04%), imipenem (76.19%) and streptomycin (4.76%) in B. melitensis
isolates. However, the increased use of these antimicrobials in Egypt in veterinary and human practices
may be the cause of the emerging of this resistance [37].
The phenotypic antimicrobial resistance against ciprofloxacin (25%), erythromycin (87.5%),
imipenem (25%) and rifampicin (37.5%) of B. abortus isolated in this study was not proved previously.
Multidrug resistant strains of B. abortus isolated from cattle in this study were reported previously
in Brazil [62]. Four isolates of B. melitensis and one isolate of B. abortus showed multidrug resistance
against ciprofloxacin, erythromycin, imipenem and rifampicin. These findings are in agreement with
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the results of Barbosa Pauletti et al. who find corresponding resistance among B. abortus isolates
from cattle in brazil [62]. All B. melitensis and B. abortus isolates in this study were sensitive to
chloramphenicol, gentamicin and tetracycline. These findings are comparable to previously published
reports in Egypt, China, Qatar and Kazakhstan [46,48,65,66].
The target for rifampicin action in Brucella as well as in other bacteria is the beta-subunit of the
DNA dependent RNA polymerase (RNAP) encoded by rpoB gene [47,51]. In this study, mutations
were identified in rpoB gene associated with phenotypic rifampicin resistant Brucella strains isolated
from clinical specimens of animals in Egypt. Mutations were detected in all phenotypically resistant
brucellae. Multiple and variable mutations were noted in each isolate along with few commonly shared
mutations among many isolates. Frequent mutations at positions 676, 677-TAC to CTC (tyrosine to
leucine, 38%) and 1435-AAG to CAG (lysine to glutamine, 23.8%) in the rpoB gene of phenotypically
resistant B. melitensis were detected. These mutations are different from previously reported mutations
(in vitro mutations) associated with rifampicin resistance in Brucella [47].
Johansen et al. reported mutations in phenotypic rifampicin resistant or intermediately resistant
B. melitensis isolates [45], which in agreement with the findings of this study with additional mutations
were detected as well as in intermediate rifampicin resistant B. melitensis.
To the best of our knowledge, this study is the first report that proved mutations in the rpoB gene
of rifampicin resistant B. abortus strains. Frequent mutations were detected at position 2890-CGT to
GGT (arginine to glycine, 37.5%).
Fluoroquinolone/quinolone resistance in Brucella is multifactorial by nature in addition to obvious
mutations of the gyrA, gyrB, parC and parE genes [51,52]. In this study, the mutations in gyrA and
gyrB genes in phenotypically resistant B. melitensis and B. abortus to ciprofloxacin were investigated.
The mutations in gyrA did not correspond with fluoroquinolone resistance mutations described by
Turkmani et al. [49], although they investigated mutations in vitro selected fluoroquinolone resistant
Brucella mutants. The mutations in the gyrB gene detected at positions 1141-AAG to GAG (lysine to
glutamine), 1144-ATC to CTC (isoleucine to leucine) and 1421-TCA to TTA (serine to leucine) of B.
melitensis considered as novel findings of this study. None of these mutations was detected in B. abortus
strains in gyrA or gyrB genes. However, the role of parC, parE and eﬄux systems cannot be ruled out
for fluoroquinolone resistance [51] as we did not investigate the changes in parC and parE genes.
Genes responsible for resistance against chloramphenicol (catB), gentamicin (Aac) and tetracycline
(tetA, tetB, tetM and tetO) were not detected in all investigated Brucella isolated in this study, which
in accordance with the phenotypic antimicrobial susceptibility results of isolated Brucella isolates.
It is also worth mentioning that all resistant Brucella strains were isolated from animals and they
showed resistance to antimicrobials clinically used in humans practice, suggesting that the source of
these Brucella strains may be of human origin. These findings point to the fact that inter-species and
intra-host species Brucella transmission is common, but spillback may occur also when chronic human
brucellosis is mistreated and resistant strains are shedded [67]. A likely scenario would be the animal
keeper interface.
The emergence of antimicrobial resistance (AMR) in bacteria is a public health issue globally
and already compromises the treatment options regarding effectiveness of antimicrobials and control
of several bacterial infections especially caused by gram-negative bacteria [68]. Wide spreading
AMR in these bacteria is likely to persist and even worsen in future due to the uncontrolled use of
antimicrobials. Rifampicin and ciprofloxacin are effective against intracellular bacteria like Brucella [33].
Higher phenotypic resistance in Brucella against these antimicrobials is likely to limits the treatment
effectiveness, owing to the increased number of infections. Emergence of multidrug resistance Brucella
in livestock species in this study may pose serious threat to humans as these bacteria often transferred
from animals to humans through food chain [69]. Being a zoonotic pathogen and given the emergence
of increased antimicrobial resistance in Brucella species, the situation with respect to hospital care may
worsen and limits the treatment options in public health settings.
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5. Conclusions
Brucellosis is a contagious and often communicable worldwide zoonosis with high morbidity
and low mortality. There has been a tremendous increase in inter host-species infection in the recent
decades, especially in developing countries when farm animal species are kept on the same premises
without biosecurity precautions. The disease is endemic in Egypt and B. melitensis and B. abortus have
been reported as the main causative agents of brucellosis in humans and animals. High phenotypic
resistance against ciprofloxacin, erythromycin, and imipenem were detected in Brucella spp. isolated
from different districts and animals species reflecting a broad geographical distribution. The molecular
identification of mutations in antimicrobial resistance associated genes highlight the mechanism of
resistance in Brucella spp. There is a need for further insights into the epidemiology and spread of
antimicrobial resistant Brucella in Egypt. The WHO regimes have to be reevaluated and awareness
among physicians about AMR needs to be raised.
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